Compare Freeport-McMoRan Inc (FCX) vs Medpace Holdings Inc (MEDP) Price & Performance

FCX trades at $69.18, down 1.92% today but maintains a bullish technical outlook with strong moving average support. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.68 exceeding expectations. Revenue growth remains stable at $25.9B, while profitability metrics show improvement with net income margin expanding to 11.38%. Recent news highlights operational strength at Grasberg mine and positive copper market tailwinds.

FCX presents a compelling investment case with analyst consensus pointing to 6.8% upside to the $73.85 price target. The company's growth initiatives and copper market exposure provide tailwinds, though investors should monitor commodity price volatility and execution risks in expansion projects. With 61% of analysts rating the stock a Buy, institutional sentiment remains positive despite recent price weakness.

MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.

Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.